ClinicalTrials.gov
Cure8 trial brief
Why This Matters
Researchers are studying how proteins from both the host and microbes in the gut relate to Crohn’s disease features. Findings could point to new noninvasive biomarkers or therapeutic strategies to correct dysbiosis, which matters for diagnosis and future treatments.
Who Should Pay Attention
Researchers studying microbiome or proteomics in IBD; gastroenterologists and clinicians involved in Crohn’s diagnosis; newly-diagnosed or suspected Crohn’s patients interested in research; translational scientists focused on biomarkers or AMP-based therapies.
Study Snapshot
Story typeClinical Reference
Evidence typeClinical trial
Enrollment40 participants
Study statusRecruiting
Source depthTrial registry record
What To Know
This is a clinicaltrials.gov record for an observational, recruiting study aiming to map host and microbial proteomic profiles in Crohn’s disease using stool, mucosal biopsies, and brushings collected at colonoscopy.
Participants (treatment-naïve suspected new-onset CD and matched controls) provide stool samples and undergo clinically indicated colonoscopy with sampling from multiple lower-intestine sites.
The study plans multi-dimensional proteomic and microbiome analyses to identify antimicrobial peptides (AMPs), candidate commensals, and potential noninvasive biomarkers or theranostic leads linked to disease features and treatment response.
The record describes eligibility, sample collection procedures, and planned characterization of gut microbiota and associated molecules but does not report results; it is a protocol/trial entry describing study design and aims.
This note is based on the trial-record content on ClinicalTrials.gov and summarizes the registration details rather than full study results.
Keep In Mind
This is a recruiting observational study protocol registered on ClinicalTrials.gov; it describes planned sample collection and analytic goals but does not provide results. Participation requires a medically indicated colonoscopy and excludes people with prior IBD treatment or recent antibiotics/steroids.
Source Details
Review the original publication for the complete reporting, methods, and context.
Clinical trial
Evidence type derived from source or registry metadata.
PublicationClinicalTrials.gov
SponsorWeizmann Institute of Science
Trial IDNCT06494826
Study typeObservational
Enrollment40 participants
Indexed viaClinicalTrials.gov
Source typeTrial registry record
PublishedSep 15, 2026, 12:00 AM
Content availableTrial registry record
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Clostridium Butyricum in Stenosing Crohn's Disease
People with stricturing Crohn’s disease currently lack effective medical treatments to prevent or reverse intestinal fibrosis; this trial explores a probiotic approach (and trehalose) aimed at stimulating autophagy, a...
Protease Regulation and Impact of Sodium as Mechanisms of Inflammation in IBD
If sodium intake influences gut proteolytic activity, microbiota and inflammation, the findings could help tailor dietary guidance and personalized nutrition strategies for people with Crohn’s disease.
Understanding role of microbiota in Crohn's disease, ulcerative colitis
The article explains how gut bacteria may contribute to IBD and summarizes common tests and treatments people are likely to encounter. It highlights emerging microbial therapies (probiotics and FMT) that some patients...